# Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary

> **NCT02636608** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 244 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02636608
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-27
- **Primary completion:** 2018-05-23
- **Final completion:** 2018-05-23
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2019-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636608, "Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02636608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*